Insider Trading disclosures for BriaCell Therapeutics Corp
The latest disclosure was made by Marc Lustig in BriaCell Therapeutics Corp where a trade of 902,935
Common Shares done at an average price of $2.2
was reported to US exchanges on May 14, 2024.
Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Client Name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Traded % |
Avg. Price |
Value |
Security Type |
|
Marc Lustig
|
Director, Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 2.21 per share. |
14 May 2024 |
902,935 |
2,542,935
|
-
|
2.2 |
2,000,001
|
Common Shares |
|
Marc Lustig
|
Director, Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
14 May 2024 |
902,935 |
902,935
|
-
|
|
-
|
Common Stock Warrants |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges